Nutrition and prostate cancer: An overview

Expert Review of Anticancer Therapy

Volumn 14, Issue 11, 2014, Pages 1295-1304

  Patel, Venita H ^a  

^a Health Via Nutrition H and v Patel Ltd Nutrition   (United Kingdom)

Author keywords

CAM; diet; lifestyle; nutraceuticals; nutrition; nutrition therapy; obesity; prostate cancer; supplements

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CARCINOGEN; CERVONIC ACID; LYCOPENE; OMEGA 3 FATTY ACID; PROSTATE SPECIFIC ANTIGEN; SATURATED FATTY ACID; SELENIUM; UNCLASSIFIED DRUG; ZYFLAMEND; ANTIOXIDANT; FAT INTAKE;

BERBERIS VULGARIS; CAMELLIA SINENSIS; CANCER RISK; CLINICAL TRIAL (TOPIC); COPTIS CHINENSIS; CURCUMA LONGA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG MECHANISM; GINGER; HUMAN; LIFESTYLE; LIPID DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONHUMAN; NUTRITION; OBESITY; OCIMUM TENUIFLORUM; OREGANO; OXIDATIVE STRESS; PHYSICAL ACTIVITY; POLYGONUM CUSPIDATUM; POMEGRANATE; PROSTATE CANCER; REVIEW; RISK REDUCTION; ROSEMARY; SCUTELLARIA BAICALENSIS; SOYBEAN; SYSTEMATIC REVIEW (TOPIC); TEA; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; DIET; DIET THERAPY; FAT INTAKE; MALE; METABOLISM; MOTOR ACTIVITY; NUTRITIONAL STATUS; PHYSIOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR;

ANTIOXIDANTS; DIET; DIETARY FATS; HUMANS; MALE; MOTOR ACTIVITY; NUTRITIONAL STATUS; PROSTATIC NEOPLASMS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84910062391     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.972946     Document Type: Review

References (84)

1. Frattaroli J, Weidner G, Dnistrian AM, et al. Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urology 2008;72(6):1319-23
2. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005; 174(3):1065-9
3. McDermott CL, Blough DK, Fedorenko CR, et al. Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer 2012;20(1):65-73
4. Wilkinson S, Farrelly S, Low J, et al. The use of complementary therapy by men with prostate cancer in the UK. Eur J Cancer Care (Engl) 2008;17(5):492-9
5. Szeto YT, Kwok TC, Benzie IF. Effects of a long-term vegetarian diet on biomarkers of antioxidant status and cardiovascular disease risk. Nutrition 2004;20(10):863-6
6. Rosato V, Edefonti V, Bravi F, et al. Nutrient-based dietary patterns and prostate cancer risk: a case-control study from Italy. Cancer Causes Control 2014;25(4):525-32
7. McGrowder DA, Jackson LA, Crawford TV. Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev 2012; 13(1):1-13
8. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17(8): 989-1003
9. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86(3):s843-57
10. Pelucchi C, Serraino D, Negri E, et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011; 21(11):835-41
11. Franz MJ. The role of nutrition therapy and dietitians in the management of the metabolic syndrome. Curr Diab Rep 2007; 7(1):60-5
12. Liu Y, Hu F, Li D, et al. Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Eur Urol 2011;60(5):1029-44
13. Rebillard A, Lefeuvre-Orfila L, Gueritat J, Cillard J. Prostate cancer and physical activity: adaptive response to oxidative stress. Free Radic Biol Med 2013;60:115-24
14. Magbanua MJ, Richman EL, Sosa EV, et al. Physical activity and prostate gene expression in men with low-risk prostate cancer. Cancer Causes Control 2014;25(4): 515-23
15. Colli JL, Colli A. Comparisons of prostate cancer mortality rates with dietary practices in the United States. Urol Oncol 2005; 23(6):390-8
16. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23(32): 8152-60
17. Chavarro JE, Stampfer MJ, Hall MN, et al. A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Am J Clin Nutr 2008;88(5): 1297-303
18. Epstein MM, Kasperzyk JL, Mucci LA, et al. Dietary fatty acid intake and prostate cancer survival in Örebro County. Sweden. Am J Epidemiol 2012; 176(3):240-52
19. Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 2010;92(5):1223-33
20. McCarty MF, DiNicolantonio JJ, Lavie CJ, O'Keefe JH. Omega-3 and prostate cancer: examining the pertinent evidence. Mayo Clin Proc 2014;89(4):444-50
21. Gu Z, Suburu J, Chen H, Chen YQ. Mechanisms of omega-3 polyunsaturated fatty acids in prostate cancer prevention. Biomed Res Int 2013;2013:824563
22. Wang Z, Fan J, Liu M, et al. Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application. Expert Opin Investig Drugs 2013;22(12):1613-26
23. van Breemen RB, Pajkovic N. Multitargeted therapy of cancer by lycopene. Cancer Lett 2008;269(2):339-51
24. Mordente A, Guantario B, Meucci E, et al. Lycopene and cardiovascular diseases: an update. Curr Med Chem 2011;18(8): 1146-63
25. Brown MJ, Ferruzzi MG, Nguyen ML, et al. Carotenoid bioavailability is higher from salads ingested with full-fat than with fat-reduced salad dressings as measured with electrochemical detection. Am J Clin Nutr 2004;80(2):396-403
26. Etminan M, Takkouche B, Caamaño-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004;13(3):340-5
27. Obermüller-Jevic UC, Olano-Martin E, Corbacho AM, et al. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr 2003;133(11):3356-60
28. Zu K, Mucci L, Rosner BA, et al. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst 2014;106(2): djt430
29. Barnes S. The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat Res Biol 2010;8(1):89-98
30. Perabo FG, Von Löw EC, Ellinger J, et al. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 2008;11(1):6-12
31. Omoni AO, Aluko RE. Soybean foods and their benefits: potential mechanisms of action. Nutr Rev 2005;63(8):272-83
32. Rabiau N, Kossä M, Braud M, et al. Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. Cancer Epidemiol 2010;34(2):200-6
33. Hwang YW, Kim SY, Jee SH, et al. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer 2009;61(5):598-606
34. Maskarinec G, Morimoto Y, Hebshi S, et al. Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men. Eur J Clin Nutr 2006;60(12):1423-9
35. Hamilton-Reeves JM, Rebello SA, Thomas W, et al. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer 2008;60(1):7-13
36. Ide H, Tokiwa S, Sakamaki K, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010; 70(10):1127-33
37. Dalais FS, Meliala A, Wattanapenpaiboon N, et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004;64(3):510-15
38. Hsu A, Bray TM, Helferich WG, et al. Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med (Maywood) 2010;235(1):90-7
39. Viuda-Martos M, Fernandez-Lopez J, Perez-Alvarez JA. Pomegranate and its many functional components as related to human health: a review. Compr Rev Food Sci Food Saf 2010;9(6):635-54
40. Basu A, Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr Rev 2009; 67(1):49-56
41. Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem 2008;19(12):848-55
42. Lansky EP, Jiang W, Mo H, et al. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs 2005;23(1):11-20
43. Koyama S, Cobb LJ, Mehta HH, et al. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res 2010;20(1):55-62
44. Malik A, Afaq F, Sarfaraz S, et al. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 2005;102(41):14813-18
45. Kasimsetty SG, Bialonska D, Reddy MK, et al. Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells. J Agric Food Chem 2009;57(22):10636-44
46. Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12(13): 4018-26
47. Paller CJ, Ye X, Wozniak PJ, et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013;16(1):50-5
48. Yang CS, Wang H. Mechanistic issues concerning cancer prevention by tea catechins. Mol Nutr Food Res 2011;55(6): 819-31
49. Sang S, Lambert JD, Ho C, et al. Green tea polyphenols. In: Encyclopedia of Dietary Supplements (2nd Edition). Coates PM, Betz JM, Blackman MR, et al. Eds.) Informa Healthcare; New York, NY: 2010. pp 402-10
50. Deka A, Vita JA. Tea and cardiovascular disease. Pharmacol Res 2011;64(2):136-45
51. Yang CS, Wang H, Li GX, et al. Cancer prevention by tea: evidence from laboratory studies. Pharmacol Res 2011;64(2):113-22
52. Zheng J, Yang B, Huang T, et al. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr Cancer 2011; 63(5):663-72
53. Chuu CP, Chen RY, Kokontis JM, et al. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 2009;275(1):86-92
54. Albrecht DS, Clubbs EA, Ferruzzi M, et al. Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chem Biol Interact 2008;171(1):89-95
55. Thomas F, Holly JM, Persad R, et al. Green tea extract (epigallocatechin-3-gallate) reduces efficacy of radiotherapy on prostate cancer cells. Urology 2011;78(2):475.e15-21
56. Kurahashi N, Sasazuki S, Iwasaki M, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008;167:71-7
57. Bettuzzi S, Brausi M, Rizzi F, et al. Chemo prevention of human prostate cancer by Oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Canctr Res 2006;66:1234-40
58. Brausi M, Rizzi F, Bettuzri S. Chemoprevention of human prostate cancer by green tea catechins: two years later. a follow-up update. Eur Urol 2008;54:472-3
59. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004;108:130-5
60. Choan E, Segal R, Jonker D, et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/ alternative therapy approach. Urol Oncol 2005;23:108-13
61. Brown KM, Arthur JR. Selenium, selenoproteins and human health: a review. Public Health Nutr 2001;4(2B):593-9
62. Tanguy S, Grauzam S, de Leiris J, et al. Impact of dietary selenium intake on cardiac health: experimental approaches and human studies. Mol Nutr Food Res 2012;56(7): 1106-21
63. Bodnar M, Konieczka P, Namiesnik J. The properties, functions, and use of selenium compounds in living organisms. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2012;30(3):225-52
64. Lunøe K, Gabel-Jensen C, Stürup S, et al. Investigation of the selenium metabolism in cancer cell lines. Metallomics 2011;3(2): 162-8
65. Kong L, Yuan Q, Zhu H, et al. The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials 2011;32(27):6515-22
66. Sarveswaran S, Liroff J, Zhou Z, et al. Selenite triggers rapid transcriptional activation of p53, and p53-mediated apoptosis in prostate cancer cells: implication for the treatment of early-stage prostate cancer. Int J Oncol 2010;36(6): 1419-28
67. Chan JM, Oh WK, Xie W, et al. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 2009;27(22):3577-83
68. Steinbrecher A, Méplan C, Hesketh J, et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 2010;19(11):2958-68
69. Klein EA. Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 1031: 234-41.2004
70. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301(1):39-51
71. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306(14):1549-56
72. Weinstein SJ, Peters U, Ahn J, et al. Serum a-tocopherol and g-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case- control study. PLoS One 2012;7(7):e40204
73. Mateljan G. The World's Healthiest Foods. 1st Edition). GMF Publishing; Canada: 2007. 780-1
74. Mateljan G. The World's Healthiest Foods. 1st Edition). GMF Publishing; Canada: 2007. 798-9
75. Thomas R, Williams M, Sharma H, et al. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer-the UK. NCRN Pomi-T study. Prostate Cancer Prostatic Dis 2014;17(2): 180-6
76. Yan J, Xie B, Capodice JL, et al. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutamide to inhibit prostate cancer cell growth. Prostate 2012;72(3):244-52
77. Huang EC, Chen G, Baek SJ, et al. Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer. Nutr Cancer 2011;63(8):1287-96
78. Capodice JL, Gorroochurn P, Cammack AS, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol 2009;7(2):43-51
79. Giudice A, Montella M. Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention. Bioessays 2006;28(2):169-81
80. Speciale A, Chirafisi J, Saija A, Cimino F. Nutritional antioxidants and adaptive cell responses: an update. Curr Mol Med 2011; 11(9):770-89
81. Nair S, Barve A, Khor TO, et al. Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforophane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin 2010;31(9):1223-40
82. Palozza P, Catalano A, Simone R, Cittadini A. Lycopene as a guardian of redox signalling. Acta Biochim Pol 2012; 59(1):21-5
83. Zhai X, Lin M, Zhang F, et al. Dietary flavonoid genistein induces Nrf2 and phase II detoxification gene expression via ERKs and PKC pathways and protects against oxidative stress in Caco-2 cells. Mol Nutr Food Res 2013;57(2):249-59
84. Yang YC, Lii CK, Wei YL, et al. Docosahexaenoic acid inhibition of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and IKK/ NF-kB pathways. J Nutr Biochem 2013; 24(1):204-12